AlbionVC’s Post

𝗧𝗵𝗲 𝗙𝗼𝘂𝗻𝗱𝗲𝗿 𝗙𝗶𝗹𝗲𝘀 by CRIMSON Founders introduces, SyzOnc, founded by  + Massachusetts Institute of Technology and Harvard University alumna Anne Carpenter, PhD | Scientific Advisor + University of Pennsylvania alumna, Karin Eisinger, PhD | CEO, + University of North Carolina at Chapel Hill alumna, Ashley M. Fuller, PhD, PhD, | CSO SyzOnc aims to develop therapies for cancer patients who have no effective treatment options. Grounded in world-class oncology and machine learning research from Penn and the Broad Institute, they are targeting matrix-rich solid tumors by tackling multi-faceted protein targets. + 𝗟𝗼𝗰𝗮𝘁𝗶𝗼𝗻: United States + 𝗙𝗼𝘂𝗻𝗱𝗲𝗱: 2023 + 𝗧𝗲𝗮𝗺 𝗦𝗶𝘇𝗲: 3 + 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆: Biotechnology, Pharmaceuticals, Artificial Intelligence (AI), Life Sciences Read the interview with Anne Carpenter: https://lnkd.in/gpnZWfN8 Crimson Founders Team Anoosheh Kalantari, Cristina Dolan, Sam Heuck #crimsonfounders #TheFounderFiles #mitalumni #HarvardAlumni #mitsloan #startups #MITStartups #healthcare #biotech #pharmaceuticals #ai #artificialintelligence

Despite its small population of fewer than 3 million people, Lithuania punches above its weight in the life sciences industry. Lithuania’s life sciences sector now boasts over 550 biotech companies and the industry continues to expand. Though still emerging as a biotech startup hub, the country is already nurturing several promising ventures. For example, Vilnius, the capital of the country, is home to a key branch of Thermo Fisher Scientific, and in 2020, Vilnius University’s Life Sciences Center joined the European Molecular Biology Laboratory network, unlocking major EU biotech investments. Here are six startups at the forefront of Lithuania’s growing biotech scene, showcasing innovations in protein engineering, gene editing, and microfluidics. 

“The world of #biotechnology is in the midst of a wave of exciting #research and #clinical advances—from #artificialintelligence-based #drugdiscovery to cell and #genetherapy, to precision #genomeediting and other newer technologies. These advances are driving new therapies for patients and fueling recoveries for the markets that generate capital for the industry, from the venture capital that powers private #startups, to the initial public offerings of more mature companies. In GEN’s flagship virtual event, The State of #Biotech—sponsored exclusively by Cytiva —we proudly host an outstanding group of research and business leaders from industry and academia to discuss the latest research developments, innovations, disruptive technologies and #regulatory changes that will spur biotech forward to bigger and better things, for patients around the world. • An opening keynote with David Altshuler MD, PhD, Executive VP and Chief Scientific Officer of @Vertex Pharmaceuticals • A keynote presentation with John F. Crowley President and CEO of the Biotechnology Innovation Organization (BIO) • Back by popular demand, the co-hosts of the popular Biotech Hangout podcast—Daphne Zohar, Brad Loncar, and Chris Garabedian—review the highs and lows of the biotech space • Atimely discussion on the state of #ai in biotech with industry experts from Google, NVIDIA, and Recursion • A conversation with Tim Harris, author of the new book In Pursuit of Unicorns: A Journey through 50 Years of Biotechnology—a crackling memoir chronicling the history of biotech • Building a path for #CRISPR therapies with Brad Ringeisen, PhD (IGI) and Sadik Kassim, PhD (Danaher) Parallel breakout sessions hosted by Cytiva The State of Biotech is  GEN’s flagship virtual event, following its successful introduction in 2022 and expansion last year. Registration is entirely free.” When: Wednesday, September 11, 2024 Time: 8:00 am PT, 11:00 am ET, 17:00 CEST #lifesciences #researchanddevelopment #stem #scienceandtechnology #science #pharma #biopharma #techbio #likeandshare

There is much cutting-edge science ongoing in Belgium and other European countries that has the potential to be translated into therapeutic programs and even new biotech companies. All you need is to bring together researchers with capital providers/investors and #ai #drugdiscovery companies, such as Insilico Medicine, to start the validation and, eventually, the IP generation process. We believe that every researcher in every lab should have access to an affordable and easy-to-use AI-powered drug discovery platform capable of novel target identification, repurposing drug candidate identification, de-novo drug design, etc. Just imagine the impact of this on the future of drug discovery. The sky is the limit! PandaOmics Chemistry42

Join me at Frontiers Health 2024 as I unveil Germany’s Tech Transfer Revolution in a fireside chat with Nicole Hecht! Curious about latest trends in tech transfer and why Saxony is a biotech powerhouse? Here is a sneak peek of what I will be talking about at the event. 👉 A general "one-size-fits-all" mentality regarding tech transfer doesn’t work for the highly regulated, high-risk, and capital-intensive life sciences sector which requires a life science-specific, comprehensive tech transfer ecosystem with interconnected support platforms. 👉 Focusing on later stage innovators like the biosaxony accelerator Medical Forge bridging the final steps to bring medical products from development to the clinic and thus to patients 👉 Saxony’s achievements include a €200 million investment 25 years ago leading to 300 companies and research institutions, employing over 15.500 people and generating nearly two billion euros in annual revenue today and our first Nobel Prize winner in Medicine. Saxony is leading in cell and gene therapy, cell biology, and radiopharmacy. 👉 Saxony is attractive for research and companies with cutting-edge research institutes like Max-Planck and dynamic SMEs. biosaxony is driving growth and supporting startups and SMEs through initiatives like Medical Forge and new life science VC funds. Saxony is the place to be for biotech innovation. Considering future biotech business or research opportunities? Come join the event and learn how to revolutionize tech transfer and look no further than Saxony – a hub of innovation and excellence! October 17-18, 2024, at Frontiers Health in Berlin. https://lnkd.in/eVSQ53gc #Biotech #Innovation #Saxony #BusinessOpportunity #ResearchOpportunity #FutureOfMedicine #Biosaxony #MedicalForge #techtransfer #commercilization #FH24 #MEDICALFORGE Lipotype biosaxony #nukliD Saxony Trade & Invest Corp. Dresden Tomorrow's Home (Wirtschaftsförderung Dresden) Dezernat für Wirtschaft, Arbeit und Digitales Stadt Leipzig Nana Bit-Avragim (she/her) Hi I am Oliver - CEO of Lipotype Inc., COO Lipotype and Chairman of board biosaxony. We are revolutionizing R&D with lipidomics. Like my post? Follow for more 🚀

Startups Exploring Diversity in Genetics and Biotechnology Research This week we spotlight startups helping close the diversity gap in healthcare. The journey towards achieving diversity in genetics and biotechnology research is critical and ongoing. Startups like Yemaachi Biotech, Hurone AI and Acclinate are pioneering innovative solutions to address the lack of diversity in genomics, biotechnology, and clinical trial research. Through their groundbreaking technologies, collaborative initiatives, and inclusive approaches, these startups are revolutionising the landscape of healthcare equity and diversity. By Henry Duah Read the full article: https://lnkd.in/ezAhCkVn Get innovation insights from The FutureList weekly. Subscribe to our newsletter here: https://bit.ly/3DVZexv #cancercare #genomics #biotechnology #clinicaltrials #artificialintelligence

𝗧𝗵𝗲 𝗙𝗼𝘂𝗻𝗱𝗲𝗿 𝗙𝗶𝗹𝗲𝘀 by CRIMSON Founders introduces, SyzOnc, founded by  + Massachusetts Institute of Technology and Harvard University alumna Anne Carpenter, PhD | Scientific Advisor + University of Pennsylvania alumna, Karin Eisinger, PhD | CEO, + University of North Carolina at Chapel Hill alumna, Ashley M. Fuller, PhD, PhD, | CSO SyzOnc aims to develop therapies for cancer patients who have no effective treatment options. Grounded in world-class oncology and machine learning research from Penn and the Broad Institute, they are targeting matrix-rich solid tumors by tackling multi-faceted protein targets. + 𝗟𝗼𝗰𝗮𝘁𝗶𝗼𝗻: United States + 𝗙𝗼𝘂𝗻𝗱𝗲𝗱: 2023 + 𝗧𝗲𝗮𝗺 𝗦𝗶𝘇𝗲: 3 + 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆: Biotechnology, Pharmaceuticals, Artificial Intelligence (AI), Life Sciences Read the interview with Anne Carpenter: https://lnkd.in/gpnZWfN8 #crimsonfounders #TheFounderFiles #mitalumni #HarvardAlumni #mitsloan #startups #MITStartups #healthcare #biotech #pharmaceuticals #ai #artificialintelligence

https://lnkd.in/d2ajUS2C This innovation will change human's future. AlphaFold 3 brings the biological world into high definition. It allows scientists to see cellular systems in all their complexity, across structures, interactions and modifications. This new window on the molecules of life reveals how they’re all connected and helps understand how those connections affect biological functions — such as the actions of drugs, the production of hormones and the health-preserving process of DNA repair. This leap could unlock more transformative science, from developing biorenewable materials and more resilient crops, to accelerating drug design and genomics research

Emerging Therapeutic Innovation Models: In last 2 years, venture and philanthropy deploy $4.5B across three companies for basic and translational research. One model claims to bypass limitations of NIH funding and academic institutions. High-level notes from press releases. Interested in your thoughts. 1. Funding: Arena $500M. Altos $3B. Xiara $1B 2. Focus: (a) Arena - determining the mechanisms of human disease and advancing new technologies to translate these insights into therapeutics through in-house biotech companies (b) Altos - restore cell health and resilience to reverse disease, injury, and the disabilities that can occur throughout life. (c) Xiara - AI Enabled Drug Discovery for traditionally undruggable targets. 3. Press Releases Arena - https://lnkd.in/e4hksYnD Altos - https://lnkd.in/etc-Ax44 Xiara - https://lnkd.in/e3-AiJjT

Biotech is Booming? The health industry in 2024 has shifted gears, moving away from traditional HealthTech toward Biotech, Drug discovery, and Genomics. Major breakthroughs in AI and gene therapies are revolutionizing healthcare, and investors are pouring money into these cutting-edge areas. In Q1 2024, BioTech startups raised a crazy $2.9 billion in venture capital. From precision oncology to regenerative medicine, companies like Obsidian Therapeutics and FogPharma are leading the way. Meanwhile, digital health platforms are seeing less enthusiasm as biotech captures the spotlight. Hiring is exploding in biotech fields like computational biology and genomics, as R&D have seen a noticeable increase in demand. The future is clear—biotech innovation is shaping the next wave of healthcare. Agree? #Biotech #DrugDiscovery #Genomics #AIinHealthcare #PrecisionMedicine #HealthTech #VentureCapital #Innovation #HealthcareTransformation #BioTechHiring #KenkoTechFutures